Bayer's Rally Faces Its Sternest Test Yet as August Deadlines Loom
Published on 07/31/2026 at 17:12 | Redaktion boerse-global.de
The shares have nearly doubled off last summer's lows, yet the debate over whether the rally is justified has rarely been more polarized. Bayer's stock closed Thursday at €48.51, up 2.10 percent on the day, as European markets rode a broadly positive earnings season — the DAX gained 0.60 percent to 25,612.03 points. But that single-day move masks a far more consequential question: after a 31.07 percent advance since January and a remarkable 75.89 percent surge over twelve months, is the Leverkusen-based group's equity finally running ahead of itself?
A Supreme Court Victory That Changed Everything
The catalyst for the dramatic re-rating came in June, when the US Supreme Court ruled 7–2 that Bayer cannot be held liable under individual US state laws in the glyphosate litigation, provided the Environmental Protection Agency had not required a warning label. The verdict triggered a single-day spike of 18.72 percent in the stock — a move that has since forced analysts to scramble for the right framework to value the company.
That reassessment has produced a striking divergence of opinion. Barclays lifted its price target from €50 to €60 while maintaining an "Overweight" rating, citing diminished risks from the Roundup lawsuits. Deutsche Bank went further, upgrading from "Hold" to "Buy" and raising its target from €45 to €60, arguing that the burden of litigation is increasingly dissipating. JPMorgan, meanwhile, has held its target steady at €50 with an "Overweight" stance ahead of the quarterly numbers. The most cautious voice comes from LBBW, which sets a €60 target yet explicitly counsels restraint on the shares themselves — a telling contradiction that underscores how far valuations have stretched.
A Chinese Filing Adds a New Dimension
While the legal saga has dominated headlines, the company has been quietly advancing its pharmaceutical pipeline. Bayer has submitted a regulatory application to China's NMPA seeking to expand the indication for its kidney drug Kerendia (finerenone) to adult patients with non-diabetic chronic kidney disease. The filing, which was confirmed by multiple news agencies on Thursday, is based on data from the Phase-3 FIND-CKD study completed in the spring. Kerendia is currently approved primarily for chronic kidney disease associated with Type-2 diabetes; an expanded approval would substantially widen the addressable patient population in one of the world's largest healthcare markets.
The strategic logic is clear. The drug is positioned as a growth driver to help offset revenue losses from patent expirations on older products, and the application leverages existing Phase-3 data rather than requiring new clinical trials. No timeline for a regulatory decision has been disclosed.
Just as Bayer is navigating complex regulatory filings to expand its market, UK employers face their own compliance obligations — and getting them wrong can be costly. Workplace safety documentation is one area where many companies unknowingly leave themselves exposed. A free toolkit with 41 ready-to-use templates and checklists helps you document risks properly and stay compliant. Download the free Risk Assessment Toolkit
The Calendar That Could Decide the Next Leg
For investors, the near-term direction hinges on two specific dates. On Tuesday, August 4, 2026, Bayer releases its half-year results at 7:30 AM CET, offering the first comprehensive look at operational performance since the Supreme Court ruling. Then, on August 19, the final hearing on the $7.25 billion Roundup class settlement — already fully approved — is scheduled, after which the legal dispute is expected to be largely concluded.
The stock's behavior around these events will be closely watched, particularly given its elevated sensitivity. The 30-day annualized volatility stands at 61.97 percent, an exceptionally high reading for a DAX constituent of this size.
The Debt Overhang That Won't Go Away
Skeptics of the current valuation point to a factor that no court ruling can resolve: the company's balance sheet. A substantial portion of operational progress, they argue, is already priced into the shares, while the debt burden will weigh on Bayer for years to come. This tension between optimistic price targets and cautionary voices explains the stock's wide trading ranges.
At Thursday's close, the shares remained 9.93 percent below their 52-week high of €53.86, reached in early July. That compares with a low of €25.09 last August — a near-doubling in under a year. The market capitalization now stands at €46.85 billion.
Managing regulatory risk isn't just a concern for pharmaceutical giants — every business that handles hazardous substances faces legal duties under COSHH regulations. Many companies underestimate which substances require assessment, and that oversight can lead to enforcement action. A free COSHH toolkit provides 43 customizable templates and checklists to help you meet your legal obligations. Get the free COSHH Toolkit
The regulatory newsflow from China adds a constructive element to the narrative, reinforcing that the pharma segment continues to develop despite the well-documented legal risks. But with the half-year report and the settlement hearing both arriving within weeks, the market's focus is likely to remain fixed on the courtroom and the income statement rather than on any single drug application. Until then, Bayer's stock sits between two camps: those who see the glyphosate risk as largely retired, and those who warn that the share price has already banked the good news.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
